Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials

被引：30
作者：
Advani, Shailesh [1 ,2 ]
Kopetz, Scott [2 ]
机构：
[1] NHGRI, Social Behav Res Branch, NIH, Bethesda, MD 20892 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd,Unit 0426, Houston, TX 77030 USA
来源：
JOURNAL OF SURGICAL ONCOLOGY | 2019年 / 119卷 / 05期
关键词：
clinical trials; colorectal cancer; immunotherapy; metastatic; targeted therapy; 1ST-LINE TREATMENT; KINASE INHIBITORS; DOUBLE-BLIND; OPEN-LABEL; FLUOROURACIL; MULTICENTER; OXALIPLATIN; IRINOTECAN; FOLFIRI; HETEROGENEITY;
D O I：
10.1002/jso.25441
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Metastatic colorectal cancer (mCRC) continues to show poor outcomes, with many patients exhausting effective standard-of-care therapy. To explore the current landscape of clinical trials for mCRC, we reviewed over 600 clinical trials that are currently ongoing for mCRC patients. Immunotherapeutic agents form approximately 39% (includes monoclonal antibodies, viruses, vaccines, and immunomodulators) of all agents and targeted therapy forms 45% (tyrosine kinase inhibitors, epigenetic modulators, and others) of all agents being investigated for mCRC.
引用
收藏
页码：642 / 652
页数：11
相关论文
共 48 条
  • [1] [Anonymous], NAT CANC I DRUG DICT
  • [2] [Anonymous], COLLECTED STUDIES IM
  • [3] [Anonymous], MON ANT APPR EMA FDA
  • [4] [Anonymous], CANC IMMUNOTHERAPY A
  • [5] [Anonymous], OPEN J GASTROENTEROL
  • [6] [Anonymous], VACC TREAT CANC
  • [7] [Anonymous], CLIN TRIALS INF
  • [8] Role of tyrosine kinase inhibitors in cancer therapy
    Arora, A
    Scholar, EM
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) : 971 - 979
  • [9] Bendardaf R, 2008, ANTICANCER RES, V28, P3865
  • [10] The causes and consequences of genetic heterogeneity in cancer evolution
    Burrell, Rebecca A.
    McGranahan, Nicholas
    Bartek, Jiri
    Swanton, Charles
    [J]. NATURE, 2013, 501 (7467) : 338 - 345
12345